Mindstate Design Labs GTM brain

Mindstate Design Labs develops experimental psychoactive therapeutics and a molecular-experience design platform for psychiatric conditions.

category

psychoactive drug development

market profile

  • text: Clinical-stage psychiatric drug development is the relevant market; the programs are investigational rather than marketed therapies.
  • text: Potential commercialization depends on clinical validation, regulation and subsequent partnerships or launch decisions.

personas

  • title: Pharma CNS business development leader
    pains:
    • Needs differentiated psychiatric pipeline assets with credible clinical evidence
    • Must assess regulatory and development risk before licensing
  • title: Clinical psychiatrist and trial investigator
    pains:
    • Major depressive disorder can include persistent anhedonia
    • Needs rigorous evidence about safety, efficacy and patient experience
  • title: Biotech investor
    pains:
    • Evaluating whether an effect-design platform translates into repeatable clinical outcomes
    • Financing long timelines and uncertain trials

icp

  • text: Pharmaceutical companies with CNS and psychiatric development portfolios and external innovation teams, as potential partners.
  • text: Academic and clinical research sites capable of controlled psychiatric drug studies, as potential trial collaborators.

message pillars

  • text: Treat subjective experience as a measurable engineering target.
  • text: Connect molecular biology to mental states.
  • text: Test targeted experiences through a sequence of clinical programs.

objections

  • objection: Does a designed subjective effect translate to clinical benefit?
    response: Distinguish early mechanistic findings from efficacy and seek results from controlled studies in the intended population.
  • objection: How mature is the therapy?
    response: The site describes an upcoming study and a pipeline of investigational programs; no approved product or commercial price is established.

competitors

  • name: COMPASS Pathways
    why: Develops psychedelic-based therapies for psychiatric indications.
  • name: Psyence Biomedical
    why: Also develops psychedelic-derived therapies for mental health.

influencers

  • name: Dillan DiNardo
    url: https://schedule.sxsw.com/2025/contributors/2195593
    why: CEO and co-founder speaking about precision psychoactive therapeutics.

keywords

  • psychedelic drug development
  • anhedonia clinical trial
  • precision psychiatry therapeutics
  • psychoactive drug discovery
  • major depressive disorder novel treatment
  • psychedelic biotech

voice

  • scientific and exploratory
  • visionary about engineering experience
  • research led

signals

  • text: A pharma company seeks external psychiatric clinical-stage assets or novel CNS modalities.
  • text: A clinical site is expanding research in depression and anhedonia.

pricing

model: unknown

motion

unknown

channels

  • scientific publications
  • conferences
  • press
  • LinkedIn

confidence

medium

Founders

  • name: Dillan DiNardo
    title: Founder/CEO
    role: CEO
    bio: Ex-VC, F500 M&A. Invested across frontier biology, software, and hardware; founded platforms in programmable genes, proteins, cells, and biological systems (AAV capsids, multispecific antibodies, TCRs, tumor microenvironment, etc.).
  • name: Tom Ray
    title: Founder
    role: Founder
    bio: BS in biology & chemistry Florida State University. MS & PhD in biology Harvard, tropical plant ecology. 1981 Society of Fellows U Michigan Ann Arbor. 1981-1998 faculty University Delaware, biology & computer science. 1993-2003 External Faculty of the Santa Fe Institute. 1993-1998 invited researcher ATR (Advanced Telecommunications Research Institute) Human Information Processing Research Labs in Japan. In 1998-present Professor of Biology & Computer Science OU. AAAS Fellow. http://tomray.me/

Back to YC companies